Targeted Agent Found Better than Immunomodulator as First-Line Strategy for Relapsing Multiple Sclerosis

Extended Protection from Disability and Cognitive Dysfunction
Seen in Active SPMS

Relapsing-Remitting Multiple Sclerosis and High-efficacy Therapies

Relapsing-Remitting Multiple Sclerosis: Oral First-line Immunomodulators

Delays in Progression of Secondary-Progressive Multiple Sclerosis Persist at 5 years

New Long-term Data Supports Early Intensive Therapy in RRMS patients

Sensitive Tool Identified for Early Detection of Alzheimer’s Disease

Latest Alzheimer’s Disease Diagnostic Criteria and Guidelines Show Importance of New Screening Tools to Detect Key Biomarkers

Challenge of Therapy Selection in Multiple Sclerosis Increases with Rapid Expansion in Drug Classes

New Migraine Guidelines Sort Through Vast Number of Therapies to Grade Evidence of Efficacy